Higher levels of soluble VCAM-1 have been documented in subjects with type 2 diabetes [35], metabolic syndrome [36], and atherosclerosis [37], and have been associated with increased CVD mortality [4]. Here, VCAM1 is linked to type 2 diabetes mellitus.